FDA Approves ORLADEYO by BioCryst for to Prevent HAE Attacks

On December 3, BioCryst Pharmaceuticals, Inc. (BCRX) announced that the FDA approved oral, once-daily ORLADEYO™ (berotralstat) to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients over the age of 12. This is the first oral non-steroidal treatment option for people with HAE. In the Phase 3 clinical trial, ORLADEYO™ significantly reduced HAE attacks at 24 weeks, and it reduced attacks through 48 weeks of therapy.


Sonal sent an alert to its subscribers at 8:45 pm on December 3, and BioCryst traded at 4:15 am on December 4 for $5.48. The stock price soared above $6 when regular market trading opened for the day. The gains continued over the next few trading sessions. BioCryst closed at $7.65 on December 10 with a five-day gain of 31%.


If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!